Research study Program year 2020 Source: CMS Open Payments

101HEMBO1-Extension

Research payments

$11,969

6 payments

Through program year 2020, $11,969 in research payments was reported against 101HEMBO1-Extension, across 6 payments, paid by Ultragenyx Pharmaceutical Inc..

Paid by: Ultragenyx Pharmaceutical Inc.
ClinicalTrials.gov: No trial number was reported for this study

By program year

2 rows

Year	Kind	Amount	Payments
2020	Research	$6,776	2
2019	Research	$5,193	4

Breakdown

Who paid Research payments · program years 2019–2020

Ultragenyx Pharmaceutical Inc. $11,969 6 payments

Who received the money Research payments · program years 2019–2020

Univ Of Mi Hospitals & Hlth Ctrs Teaching hospital · MI $5,193 4 payments
University of Florida Organisation paid for research $3,776 1 payment
Arkansas Children S Research Organisation paid for research $3,000 1 payment

Usually the institution or organisation running the study, not a person.

What the money was spent on Research payments · program years 2019–2020

Patient care $6,776 2 payments
Other $5,193 4 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

Records

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

3 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.